X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SANOFI INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SANOFI INDIA CIPLA/
SANOFI INDIA
 
P/E (TTM) x 33.8 37.2 90.8% View Chart
P/BV x 2.9 7.0 41.9% View Chart
Dividend Yield % 0.6 0.5 106.4%  

Financials

 CIPLA   SANOFI INDIA
EQUITY SHARE DATA
    CIPLA
Mar-18
SANOFI INDIA
Dec-17
CIPLA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6634,945 13.4%   
Low Rs4793,901 12.3%   
Sales per share (Unadj.) Rs189.01,081.8 17.5%  
Earnings per share (Unadj.) Rs17.6141.6 12.4%  
Cash flow per share (Unadj.) Rs34.0185.9 18.3%  
Dividends per share (Unadj.) Rs3.0033.00 9.1%  
Dividend yield (eoy) %0.50.7 70.4%  
Book value per share (Unadj.) Rs176.7868.8 20.3%  
Shares outstanding (eoy) m805.1223.03 3,496.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.1 73.9%   
Avg P/E ratio x32.531.2 103.9%  
P/CF ratio (eoy) x16.823.8 70.5%  
Price / Book Value ratio x3.25.1 63.5%  
Dividend payout %17.123.3 73.1%   
Avg Mkt Cap Rs m459,724101,862 451.3%   
No. of employees `00023.63.2 728.9%   
Total wages/salary Rs m26,9013,685 730.0%   
Avg. sales/employee Rs Th6,446.17,691.9 83.8%   
Avg. wages/employee Rs Th1,139.41,137.7 100.1%   
Avg. net profit/employee Rs Th600.01,006.5 59.6%   
INCOME DATA
Net Sales Rs m152,19324,914 610.9%  
Other income Rs m3,577807 443.2%   
Total revenues Rs m155,76925,721 605.6%   
Gross profit Rs m28,2645,372 526.1%  
Depreciation Rs m13,2281,022 1,294.3%   
Interest Rs m1,14211 10,384.5%   
Profit before tax Rs m17,4705,146 339.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5011,886 132.6%   
Profit after tax Rs m14,1663,260 434.5%  
Gross profit margin %18.621.6 86.1%  
Effective tax rate %14.336.6 39.1%   
Net profit margin %9.313.1 71.1%  
BALANCE SHEET DATA
Current assets Rs m108,14114,432 749.3%   
Current liabilities Rs m38,3226,010 637.6%   
Net working cap to sales %45.933.8 135.7%  
Current ratio x2.82.4 117.5%  
Inventory Days Days9761 159.3%  
Debtors Days Days7428 261.3%  
Net fixed assets Rs m109,4117,991 1,369.2%   
Share capital Rs m1,610230 699.2%   
"Free" reserves Rs m140,68219,778 711.3%   
Net worth Rs m142,29220,008 711.2%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60627,770 823.2%  
Interest coverage x16.3468.8 3.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.9 74.2%   
Return on assets %6.711.8 56.8%  
Return on equity %10.016.3 61.1%  
Return on capital %10.025.8 38.6%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,6916,306 819.7%   
Fx outflow Rs m21,0335,257 400.1%   
Net fx Rs m30,6581,049 2,922.6%   
CASH FLOW
From Operations Rs m14,6284,351 336.2%  
From Investments Rs m-8,540-787 1,085.1%  
From Financial Activity Rs m-3,855-1,884 204.6%  
Net Cashflow Rs m2,4311,680 144.7%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 60.4 34.4%  
Indian inst/Mut Fund % 12.2 14.4 84.7%  
FIIs % 23.7 14.6 162.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 15,184 1,061.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  PFIZER  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 20, 2018 (Close)

TRACK CIPLA

CIPLA - FRESENIUS KABI ONCO. COMPARISON

COMPARE CIPLA WITH

MARKET STATS